Showing papers in "Clinical Cornerstone in 2005"

TL;DR: Several promising pharmacologic interventions that may have an important role in the management of metabolic syndrome by treating adipose tissue-mediated metabolic disturbances are in the early stages of development.

TL;DR: The metabolic syndrome is a common cluster of risk factors for coronary heart disease and type 2 diabetes mellitus that includes obesity, elevated blood pressure, insulin resistance, and dyslipidemia that appears to be an important risk factor for atherogenic cardiovascular disease and diabetes.

TL;DR: The investigational agent, rimonabant, has shown promise in attacking atherogenic dyslipidemia from several vantage points by affecting glucose, HDL-C, triglycerides, and waist circumference in patients who are prone to atheism.

TL;DR: Current challenges in diabetes management include: optimizing the use of currently available therapies to ensure adequate glycemic, blood pressure, and lipid control and to reduce complications.

TL;DR: Extending routine systematic assessment from cardiovascular risk to cardiometabolic risk--that is, risk for developing CVD and/or DM--and increasing the understanding of the basic mechanisms that regulate energy balance and metabolic risk factors are needed to address this impending epidemic of DM.

TL;DR: A number of studies looking into patient preferences for a particular class of treatment method over another, and also for individual treatments within classes are discussed, finding patients appear to prefer oral treatments to others.

TL;DR: PDE5 therapy, compared with placebo, significantly improves scores on the International Index of Erectile Function and has been found to be effective in special clinical populations, such as those with prostate cancer, diabetes, and cardiovascular disease.

TL;DR: Physical organic causes are now thought to account for most cases of erectile dysfunction (ED), although there is often a psychogenic contribution to the condition.

TL;DR: Greater awareness of the epidemiology of V TE, the consequences of VTE, and the risk factors for VTE can help health care providers take appropriate preventive measures to reduce the incidence of Vte.

TL;DR: Erectile dysfunction remains a source of embarrassment for many men and health professionals, and it remains under-reported, under-recognized, and undertreated.

TL;DR: The use of SNP, along with other diagnostic tools, can enable care providers to facilitate and optimize care of heart failure patients in a variety of clinical settings and emerging clinical data will help further refine biomarker-guided therapeutic and monitoring strategies involving BNP.

TL;DR: Evaluation of the analytical performance of a chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin I in human serum and plasma on an automated immunoASSay instrument system (ARCHITECT) to aid in the diagnosis of myocardial infarction is discussed.

TL;DR: A new type of T gel has improved pharmacokinetic and clinical profiles compared with other forms of T therapy, and has been shown to be effective in older men and in men with HIV infection, despite unsatisfactory response to earlier T-gel therapy.

TL;DR: Consideration of Testim 1% gel in HIV patients who have an inadequate response to prior T therapy is encouraged, although it is difficult to estimate the contribution of nonspecific study effects in this trial.

TL;DR: Weight loss, particularly a reduction in waist circumference, improves insulin sensitivity, lipid profile, and serum adipocytokines, thereby reducing the risk of developing chronic disease and CVD.

TL;DR: Oral treatments, which are minimally invasive, are the favoured first-line option for treatments and include the phosphodiesterase-5 (PDE5) inhibitors, and dopamine agonists such as apomorphine.

TL;DR: The key biochemical event in erectile function is an increase in levels of cyclic guanosine monophosphate, which causes smooth-muscle relaxation and allows an erection to occur, which is mediated by nitric oxide, produced by neurons and elsewhere, which acts as a gaseous messenger molecule.

TL;DR: There is a relationship between the decision statistics used in screening for left ventricular dysfunction and the type of diagnostic assay used to optimize test performance, and the MEIA on AxSYM demonstrated greater sensitivity than POC Triage BNP assay in minimally symptomatic patients with heart failure.

TL;DR: The medical history is crucial because ED is associated with so many common disorders and their treatment, and a range of validated questionnaires may be used in taking the history, which helps identify whether the ED is largely physical or psychogenic.

TL;DR: Consideration of Testim 1% gel in patients who have an inadequate response to prior T therapy is encouraged, although it is difficult to estimate the contribution of nonspecific study effects in this trial.

TL;DR: Targeting the endocannabinoid (EC) system represents a new approach to treating visceral obesity and reducing cardiovascular risk factors.

TL;DR: In carefully screened and managed patients, LMWH offers a cost-effective, convenient, and safe alternative to UFH for thrombosis management in VTE and NSTE ACS.

TL;DR: Increased awareness about the full range of options for VTE prophylaxis can help health care providers select the appropriate course of action to help reduce the incidence of VTE among patients with acute medical illnesses.

TL;DR: A review of CV risk factors in patients with the metabolic syndrome is beneficial for clinicians to apply in the care of their patients, along with a discussion about strategies for identifying at-risk patients and managing CVD risk for these patients.

TL;DR: A variety of human and animal studies have raised the question of whether T4 monotherapy is sufficient to restore tissue and organ intracellular T3 levels to normal, and some evidence, albeit controversial, suggests that the addition of T3 (Cytomel) to T4 replacement therapy may improve patients' quality of life, psychometric performance and mood as discussed by the authors.

TL;DR: Improved systems are needed in medically ill patients to help improve outcomes and compliance for the use of VTE prophylaxis, an objective supported by the recent guidelines of the American College of Chest Physicians.

TL;DR: Three large randomized clinical trials have demonstrated the efficacy and safety of prophylaxis of VTE in the medical setting and support the evidence-based recommendations for systematic use of thromboprophylaxis in this setting.